- Home
- TRIB vs ADIL Comparison
TRIB vs ADIL Comparison
Compare TRIB & ADIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRIB | ADIL |
|---|---|---|
| Founded | 1992 | 2010 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 6.1M |
| IPO Year | 1996 | 2017 |
Fundamental Metrics
Financial Performance| Metric | TRIB | ADIL |
|---|---|---|
| Price | $12.45 | $2.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $37.50 |
| AVG Volume (30 Days) | ★ 724.2K | 34.7K |
| Earning Date | 05-22-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.51 | N/A |
| Revenue Next Year | $13.14 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $0.13 |
| 52 Week High | $9.85 | $5.17 |
Technical Indicators
Market Signals| Indicator | TRIB | ADIL |
|---|---|---|
| Relative Strength Index (RSI) | 98.39 | 60.49 |
| Support Level | $0.64 | $2.60 |
| Resistance Level | N/A | $2.98 |
| Average True Range (ATR) | 0.53 | 0.17 |
| MACD | 1.23 | -0.01 |
| Stochastic Oscillator | 95.82 | 88.89 |
Price Performance
Historical ComparisonAbout TRIB Trinity Biotech plc
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.